电子烟之争:什么才算证据?
本文比较了2018年冬NASEM与PHE两份电子烟公共卫生评估,指出两者在关键公共卫生政策结论上差异显著。差异源于各自核心问题不同:NASEM关注保护非吸烟者,采用预防性标准强调因果证据;PHE关注减轻吸烟者疾病负担,侧重即时危害相关证据。优先事项决定了何种证据被采纳。
要点
- NASEM以预防性标准要求因果证据,重点保护非吸烟者免受尼古丁暴露和吸烟正常化风险。
- PHE以减轻吸烟者疾病负担为优先,采纳与即时危害相关且有意义证据。
- 竞争性优先事项决定了电子烟对吸烟者、非吸烟旁观者及儿童青少年影响的证据选择。
核心结论
- 两份评估在电子烟公共卫生政策结论上差异显著,源于各自核心问题与证据标准不同。
- NASEM强调预防性标准与因果证据,PHE侧重即时危害相关证据。
研究设计与样本
- 本文为对2018年冬NASEM与PHE两份电子烟公共卫生评估的比较分析。
主要发现
- NASEM核心问题为保护非吸烟者免受尼古丁暴露和吸烟正常化风险,要求因果证据。
- PHE优先减少当前吸烟者疾病负担,采纳与即时危害相关且有意义证据。
- 优先事项差异决定电子烟对吸烟者、非吸烟旁观者及儿童青少年影响的证据选择。
临床怎么用
- 理解价值取向与问题框架如何影响证据选择,对解读电子烟政策评估至关重要。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Two major public health evaluations of e-cigarettes-one from the National Academies of Science, Engineering, and Medicine (NASEM), the other from Public Health England (PHE)-were issued back to back in the winter of 2018. While some have read these analyses as broadly consistent, providing support for the view that e-cigarettes could play a role in smoking harm reduction, in every major respect, they come to very different conclusions about what the evidence suggests in terms of public health policy. How is that possible? The explanation rests in what the 2 reports see as the central challenge posed by e-cigarettes, which helped to determine what counted as evidence. For NASEM, the core question was how to protect nonsmokers from the potential risks of exposure to nicotine and other contaminants or from the risk of smoking combustible cigarettes through renormalization. A precautionary standard was imperative, making evidence that could speak most conclusively to the question of causality paramount. For PHE, the priority was how to reduce the burdens now borne by current smokers, burdens reflected in measurable patterns of morbidity and mortality. With a focus on immediate harms, PHE turned to evidence that was "relevant and meaningful." Thus, competing priorities determined what counted as evidence when it came to the impact of e-cigarettes on current smokers, nonsmoking bystanders, and children and adolescents. A new clinical trial demonstrating the efficacy of e-cigarettes as a cessation tool makes understanding how values and framing shape core questions and conclusive evidence imperative.
引用
- Fairchild AL, Bayer R, Lee JS, et al. The E-Cigarette Debate: What Counts as Evidence? Am J Public Health. 2019. PMID: 31095415. doi:10.2105/AJPH.2019.305107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。